Oxyrane rounds up $26.5M for ERT work

We have news of one more biotech venture round this morning: The Dutch biotech Oxyrane has garnered $26.5 million in venture cash to back their work on enzyme replacement therapies for lysosomal storage diseases. Forbion Capital Partners led the way with Morningside Groups and New Science Ventures, an existing investor.  "This syndicate of respected, experienced investors will provide us with the support necessary to advance our exciting pipeline towards the clinic," said CEO Michael Campbell. "Oxyrane is now well positioned to progress our research into clinical trials in Pompe disease in order to explore the potential benefits of our technology in people with this debilitating and potentially fatal disorder." Release

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.